Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.…
Fractyl Health, Inc. Common Stock Q3 2026 Earnings Call Summary
Fractyl Health (NASDAQ: GUTS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 100 employees.
The shares were at 0.8200 USD on 20 November 2026, down 93.8% over 52 weeks. Its 52-week range is 0.7840 USD to 29.34 USD: the price is 97.2% below the high and 4.6% above the low.
Its market capitalisation is 10.88M USD.
Fractyl Health reports an operating margin of 0.0%.
Its debt exceeds its cash by 13.60M USD, a debt-to-equity ratio of 6.52. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 23 March 2027.